bioRxiv · 17 Sept 2026 · Preprint · Open access

CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancer

Gini, Gui + 13 more

Open access
5 cites

Abstract ↗AI briefThe abstract is read at the publisher; the brief is JClub's.

The AI brief for this paper is being written. Open it in JClub to read the paper with the brief as soon as it lands.

Read the brief in JClub →

Rare EGFRm NSCLC: More First-Line Options Emerge.
Cancer Discovery · 1 July 2026 · News
Next-generation tyrosine kinase inhibitor sunvozertinib shows superior efficacy over chemotherapy as a first-line treatment for EGFR exon 20 insertion non-small cell lung cancer in the phase III WU-KONG28 trial.
- In the news
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42224429
Open in JClub
Ivonescimab Plus Chemo Extends Squamous NSCLC Survival.
Cancer Discovery · 1 July 2026 · News
Ivonescimab combined with chemotherapy improves overall survival in advanced squamous NSCLC, showing a significant benefit over existing immunotherapy-chemotherapy regimens in a Chinese trial.
- In the news
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42240226
Open in JClub
Blood Protein Test Predicts Lung Cancer Years before Diagnosis.
Cancer Discovery · 16 June 2026 · News
A 14-protein blood test predicts lung cancer risk over 5 years before detection, including in never-smokers outside current screening guidelines.
- In the news
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42299102
Open in JClub

Journals this month

All journals →

Moving areas, week to 3 Oct 2026

All research areas →

Read